Table 6.

Odds ratios (and 95% confidence intervals) for 30 day and one year mortality, comparing the different in-hospital treatment of atrial fibrillation

	Unadjusted	Adjusted for baseline characteristics*	Adjusted for baseline characteristics and pre-AF complications†
30 day mortality
Class I antiarrhythmic agents‡	0.30 (0.15 to 0.63)	0.38 (0.18 to 0.81)	0.42 (0.19 to 0.89)
Sotalol	0.21 (0.05 to 0.85)	0.26 (0.06 to 1.12)	0.31 (0.07 to 1.32)
Amiodarone	1.23 (0.81 to 1.87)	1.21 (0.77 to 1.90)	1.08 (0.68 to 1.74)
Electrical cardioversion	1.22 (0.75 to 2.01)	1.24 (0.73 to 2.10)	1.16 (0.66 to 2.03)
1 year mortality
Class I antiarrhythmic agents‡	0.41 (0.24 to 0.70)	0.54 (0.30 to 0.95)	0.58 (0.33 to 1.04)
Sotalol	0.19 (0.06 to 0.63)	0.26 (0.08 to 0.85)	0.31 (0.09 to 1.02)
Amiodarone	1.12 (0.78 to 1.63)	1.14 (0.75 to 1.73)	1.03 (0.67 to 1.57)
Electrical cardioversion	1.24 (0.81 to 1.91)	1.33 (0.82 to 2.16)	1.27 (0.78 to 2.09)

*Adjusted for grouping of atrial fibrillation (AF) including paroxysmal AF, chronic AF, and no previous AF; pulse rate; systolic blood pressure; age; history of myocardial infarction; angina; percutaneous transluminal coronary angioplasty; Killip class; and smoking class (previous, current, never).

†In addition to the above demographics, adjusted for significant pre-AF complications including worsening heart failure, shock, acute ventricular septal defect, and stroke.

‡Includes procainamide, quinidine, disopyramide, encainide, flecainide, and propafenone.